A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine Against Shigella Sonnei Administered Intramuscularly to Adults From a Shigellosis-Endemic Country
Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2017.01884
Full Text
Open PDFAbstract
Available in full text
Date
December 22, 2017
Authors
Publisher
Frontiers Media SA